Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Arch Neurol 56:179-187, Hauser,R.A.,et al, 1999
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Transient Acute Depression Induced by High-Frequency Deep-Brain Stimulation
NEJM 340:1476-1480,1500, Bejjani,B-P.,et al, 1999
Clinicopath Conf:Multisystem Neurodegenerative Disease with Dementia Pugilistica
NEJM 340:1269-1277, Case 12-1999, 1999
The Effect of Estrogen Replacement on Early Parkinson's Disease
Neurol 52:1417-1421, Sanders-Pullman,R.,et al, 1999
Prevalence and Clinical Correlates of Psychotic Symptoms in parkinson Disease
Arch Neurol 56:595-601, Aarsland,D.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Paroxysmal Dyskinesias in Patients with HIV Infection
Neurol 52:109-114, Mirsattari,S.M.,et al, 1999
Progression of Parkinsonian Signs in Parkinson Disease
Arch Neurol 56:334-337, Louis,E.D.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Neurologic Side Effects in Neuroleptic-Naive Patients Treated with Haloperidol or Risperidone
Neurol 52:782-785, Rosebush,P.I.&Mazurek,M.F., 1999
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Susceptibility to Neuroleptic Malignant Syndrome in Parkinson's Disease
Neurol 52:777-781, Ueda,M.,et al, 1999
Multicentre European Study of Thalamic Stimulation in Paarkinsonisn and Essential Tremor
JNNP 66:289-296, Limousin,P.,et al, 1999
Effectiveness of Anticholinergics and Neuroleptic Dose Reduction on Neuroleptic-Induced Pleurothotonus (the Pisa Syndrome)
J Clin Psychopharmacol 19:277-280, Suzuki,T.,et al, 1999
Dementia Following Treatment of Brain Tumors with Radiotherapy Administered Alone or in Combination with Nitrosourea-Based Chemotherapy: A Clinical and Pathological Study
J Neurooncol 41:137-149, Vigliani,M.C.,et al, 1999
Posterior Cerebral Artery Syndromes
, Caplan,L.R. &Bogousslavsky,J., 1998
Post-Traumatic Shoulder 'Dystonia':Persistent Abnormal Postures of the Shoulder After Minor Trauma
Neurol 51:1205-1207, Thyagarajan,D.,et al, 1998
Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998
Pallidotomy for Generalized Dystonia
Movement Disorders 13:693-698, Ondo,W.G.,et al, 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 339:1105-1111, Limousin,P.,et al, 1998
Unilateral Thalamic Deep Brain Stimulation for Refractory Essential Tremor and Parkinson's Disease Tremor
Neurol 51:1063-1069, Ondo,W.,et al, 1998
Bilateral High-Frequency Stimulation of the Internal Globus Pallidus in Advanced Parkinson's Disease
Ann Neurol 44:953-961, Volkmann,J.,et al, 1998
Long Term Results of Botulinum Toxin Type A (Dysport) in the Treatment of Hemifacial Spasm:A Report of 175 Cases
JNNP 64:751-757, Jitpimolmard,S.,et al, 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Postmenopausal Estrogen Use and Parkinson's Disease with and without Dementia
Neurol 50:1141-1143, Marder,K.,et al, 1998
An Unusual Case of Creutzfeldt-Jakob Disease
Neurol 51:617-619, Vingerhoets,F.J.G.,et al, 1998
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Slater Revisited:6 Year Follow Up Study of Pts with Medically Unexplained Motor Symptoms
BMJ 316:582-586, 5641998., Crimlisk,H.L.,et al, 1998
Progressive Supranuclear Palsy, A Survey of the Disease Course
Neurol 50:1637-1647, Santacruz,P.,et al, 1998
Pharmacological Therapy in Progressie Supranuclear Palsy
Arch Neurol 55:1099-1102, Kompoliti,K.,et al, 1998
An Open-Label Trial of Gabapentin Treatment of Paroxysmal Symptoms in Multiple Sclerosis Patients
Neurol 51:609-611, Solaro,C.,et al, 1998
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Long-Term Effect of Botulinum Toxin in Impairment and Functional Health in Cervical Dystonia
Neurol 50:1461-1463, Brans,J.W.M.,et al, 1998
Atrophy of the Corpus Callosum, Cortical Hypometabolism, and Cognitive Impairment in Corticobasal Degeneration
Arch Neurol 55:609-614, Yamauchi,H.,et al, 1998
Hemifacial Spasm:Clinical Findings and Treatment
Muscle & Nerve 21:1740-1747, Wang,A & Jankovic,J, 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998
Olfactory Dysfunction in Guamanian ALS,Parkinsonism,and Dementia
Neurol 51:1672-1677, Ahlskog,J.E.,et al, 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Natural History & Survival of 14 Pts with Corticobasal Degeneration Confirmed as Postmortem Exam
JNNP 64:184-189, Wenning,G.K.,et al, 1998
Hereditary Form of Parkinsonism-Dementia
Ann Neurol 43:768-781, Muenter,M.D.,et al, 1998
The Risk of Parkinson's Disease with Exposure to Pesticides, Farming, Well Water, and Rural Living
Neurol 50:1346-1350, Gorell,J.M.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Functional Neurosurgery for parkinson's Disease, Has Come a Long Way, Though Much Remains Experimental
BMJ 316:1259-1260, Quinn,N.&Bhatia,K., 1998
Pallidotomy for Parkinson's Disease:Hitting the Target
Lancet 351:998-999, Golbe,L.I., 1998